SOUTH SAN FRANCISCO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and nine months ending September 30, 2011 and provided an update on recent clinical and corporate progress.
